AIC246 is currently is in Phase IIb trial.
AiCuris CEO Rubsamen-Schaeff said the orphan drug status will also support the company in the development of AIC246 as it gives easier access to scientific support by the agencies.
AiCuris CSO Holger Zimmermann said they believe that they are developing a therapy that will prove to be both effective and safe and at the same time remains efficacious, if resistance has developed against the marketed drugs.